Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like GlaxoSmithKline Poaches New CSO From Google's Calico November 8, 2017 Pfizer Expects to Hire 80 New Staffers After Completion of $200 Million R&D Facility June 27, 2017 Pharming Group Report On Preliminary Financial Results For 2016 March 8, 2017
